Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
Representing 15% to 20% of all invasive breast cancers, adjuvant systemic treatment for early-stage, high-risk triple-negative breast cancer (TNBC) is preferentially done in the neoadjuvant setting based on a chemotherapy backbone of anthracyclines and taxanes. Pathological complete response to neoa...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-06-01
|
| Series: | Breast Cancer: Basic and Clinical Research |
| Online Access: | https://doi.org/10.1177/11782234221107580 |
| _version_ | 1828804213655732224 |
|---|---|
| author | Diogo Silva Alexandra Mesquita |
| author_facet | Diogo Silva Alexandra Mesquita |
| author_sort | Diogo Silva |
| collection | DOAJ |
| description | Representing 15% to 20% of all invasive breast cancers, adjuvant systemic treatment for early-stage, high-risk triple-negative breast cancer (TNBC) is preferentially done in the neoadjuvant setting based on a chemotherapy backbone of anthracyclines and taxanes. Pathological complete response to neoadjuvant treatment constitutes the main objective, regarding its correlation with oncological outcomes. The optimal neoadjuvant regimen to achieve the highest rates of pathological complete response is still under investigation, with the increasing knowledge on the molecular pathways, genomic sequencing, and immunological profile of TNBC allowing for the development of a wide array of new therapeutic options. This review aims to summarize the current evidence and ongoing clinical trials of new therapeutic options for the neoadjuvant treatment of TNBC patients. |
| first_indexed | 2024-12-12T07:37:56Z |
| format | Article |
| id | doaj.art-c804432bfa4040a983d916285fee23e8 |
| institution | Directory Open Access Journal |
| issn | 1178-2234 |
| language | English |
| last_indexed | 2024-12-12T07:37:56Z |
| publishDate | 2022-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Breast Cancer: Basic and Clinical Research |
| spelling | doaj.art-c804432bfa4040a983d916285fee23e82022-12-22T00:32:53ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342022-06-011610.1177/11782234221107580Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast CancerDiogo SilvaAlexandra MesquitaRepresenting 15% to 20% of all invasive breast cancers, adjuvant systemic treatment for early-stage, high-risk triple-negative breast cancer (TNBC) is preferentially done in the neoadjuvant setting based on a chemotherapy backbone of anthracyclines and taxanes. Pathological complete response to neoadjuvant treatment constitutes the main objective, regarding its correlation with oncological outcomes. The optimal neoadjuvant regimen to achieve the highest rates of pathological complete response is still under investigation, with the increasing knowledge on the molecular pathways, genomic sequencing, and immunological profile of TNBC allowing for the development of a wide array of new therapeutic options. This review aims to summarize the current evidence and ongoing clinical trials of new therapeutic options for the neoadjuvant treatment of TNBC patients.https://doi.org/10.1177/11782234221107580 |
| spellingShingle | Diogo Silva Alexandra Mesquita Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer Breast Cancer: Basic and Clinical Research |
| title | Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer |
| title_full | Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer |
| title_fullStr | Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer |
| title_full_unstemmed | Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer |
| title_short | Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer |
| title_sort | evolving evidence for the optimization of neoadjuvant therapy in triple negative breast cancer |
| url | https://doi.org/10.1177/11782234221107580 |
| work_keys_str_mv | AT diogosilva evolvingevidencefortheoptimizationofneoadjuvanttherapyintriplenegativebreastcancer AT alexandramesquita evolvingevidencefortheoptimizationofneoadjuvanttherapyintriplenegativebreastcancer |